Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05821400
NCT05821400
Recruiting
Not Applicable

Cognitive Changes in Mild Cognitive Impairment Without Orthostatic Hypotension

Fujian Medical University Union Hospital1 site in 1 country200 target enrollmentStarted: March 1, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy Controls Without Orthostatic Hypotension

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
200
Locations
1
Primary Endpoint
Changes in Montreal Cognitive Assessment (MoCA) scores after 3 months.
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Background: In recent years, the changes of cognitive function in mild cognitive impairment have attracted attention.

Methods/design: We will follow up at 3. The primary outcome will be the measurement of cognitive function using neuropsychological assessment scales such as MOCA, MMSE, etc... Minor variables will be included plasma biomarkers (Aβ, Tau, GFAP, etc.), multimodal brain electrophysiology (P300, VP300, heart rate variability, etc.), and neuroimaging indicators (NODDI).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
30 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Clinically diagnosed mild cognitive impairment

Exclusion Criteria

  • •Patients with orthostatic hypotension
  • •Patients with other neurological disorders.
  • •Pregnant or lactating women.

Outcomes

Primary Outcomes

Changes in Montreal Cognitive Assessment (MoCA) scores after 3 months.

Time Frame: Participants will be followed up for 3 months after baseline.

The MOCA scale scores range from 0 to 30, with higher scores indicating better cognition

Secondary Outcomes

  • Changes in Blood pressure (mmHg) after 3 months.(Participants will be followed up for 3 months after baseline.)
  • Changes in Plasma tau levels after 3 months.(Participants will be followed up for 3 months after baseline.)
  • Changes in Plasma amyloid protein levels after 3 months.(Participants will be followed up for 3 months after baseline.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Cognitive Impairment in Atrial FibrillationAtrial FibrillationMild Cognitive ImpairmentDementia
NCT01816308Texas Cardiac Arrhythmia Research Foundation888
Recruiting
Not Applicable
prospective study of mild cognitive impairment and dementia in Kurashiki.
JPRN-UMIN000035971Kawasaki Medical School1,000
Recruiting
Not Applicable
Effectiveness of an Intervention Using Observation/Action Therapy Among Patients With Mild Cognitive ImpairmentMild Cognitive ImpairmentAge-associated Memory Impairment
NCT05934344Universidad Europea de Madrid45
Unknown
Not Applicable
Clinical Outcomes in Elderly Patients With Preoperative Cognitive DysfunctionCognitive DeclineAge ProblemOutcome
NCT03143595Zhongda Hospital500
Not yet recruiting
Phase 3
The survey to find out the number of individuals having difficulty in remembering or learning new things and its effect on mobility and balance in elderly population in Hubli Dharwad
CTRI/2019/09/021124Chougule Snehal Sanjay